This innovative new accelerator programme will provide significant funding and support for selected start-ups, with office and lab space in the Milner Research Labs.
Written by
ndo23
Milner Therapeutics Symposium 2019
Registration for the Milner Therapeutics Symposium on June 25th 2019 is now open! This Symposium is an opportunity for scientists from academia and industry to discuss their latest research and its potential to be applied in pharma and biotech towards new treatments. It is our key networking event to foster collaborations within the Milner Therapeutics …
Cancer Research UK and AstraZeneca launch world class functional genomics centre at the Milner Research Labs
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the Milner Research Labs in Cambridge, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer. The Milner Research Labs, which will open in March 2019 on the Cambridge …
Milner Therapeutics Symposium 2018
Our Annual Symposium is an opportunity for scientists from academia and industry to discuss the latest academic and clinical research and how it could be applied in the pharma and biotech industry to develop new treatments. It is our key networking event for Milner Therapeutics Institute alliance partners.
The Milner Institute's Namshik Han takes part in a panel discussion at #Impact18
Computational Biology Programme Lead Namshik Han was on the panel at #Impact18 earlier this month, discussing how artificial intelligence is reshaping biotechnology and healthcare sectors. You can listen to Namshik’s ideas around AI in healthcare research, including his predictions for the future, in the video below.
Milner facilitates strategic partnership between Nemesis and Shionogi
SHIONOGI INVESTS IN NEMESIS TECHNOLOGY Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M from a syndicate of new investors including Shionogi & Co Ltd, Coastal International Holdings and Wren Capital in addition to existing investors the Development Bank of …
Milner Affiliated company MedAnnex Ltd Receives SMART: SCOTLAND R&D Award
Scottish Enterprise will contribute up to £423,000 towards the industrial development of a novel antibody to treat autoimmune diseases Milner Affiliated company MedAnnex Ltd, an innovative biotechnology company developing new therapies to treat autoimmune diseases, has announced that it has been awarded up to £423,000 via the SMART: SCOTLAND programme. Alongside backing from MedAnnex’s investors, this …
Registration is OPEN for The Milner Institute's 2018 Symposium
Registration for The Milner Therapeutics Symposium is now open! This Symposium is an opportunity for scientists from academia and industry to discuss the latest academic and clinical research and how it could be applied in the pharma and biotech industry to develop new treatments. It is our key networking event for Milner Therapeutics Institute alliance …
The Milner Institute's new building starts to take shape
Our new building is starting to take shape now, ready for the opening in October. The Milner Therapeutics Institute will have research laboratories within the Capella Building, which is on the Cambridge Biomedical Campus. The laboratories will house research groups from the Cambridge research community. A research facility will also be established, accessible to …
LifeArc and Milner Therapeutics Institute announce a new partnership in artificial intelligence and machine learning for target discovery
London and Cambridge, UK 23 January 2018 – LifeArc®, the UK-based medical research charity and the Milner Therapeutics Institute at the University of Cambridge today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases. Under this new collaborative project, cutting-edge machine learning approaches will be developed, validated and …